Nautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced plans to report its financial results for Q2 of fiscal year 2021 on August 10, 2021, before the market opens. A webcast conference call will follow at 5:00 a.m. PT / 8:00 a.m. ET to discuss the results, business developments, and future outlook. Nautilus focuses on pioneering a single-molecule protein analysis platform to advance proteomics, aiming to enhance accessibility to proteomic data and contribute to advancements in human health and medicine.
Positive
- Upcoming financial results announcement for Q2 2021, potentially revealing key growth metrics.
- Emphasis on a pioneering proteomics platform could attract investor interest.
Negative
- No specific financial data or metrics provided in the announcement, leading to uncertainty about performance.
News Market Reaction – NAUT
In the trading session that priced this news, NAUT declined 2.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter of fiscal year 2021 before market open on Tuesday, August 10th, 2021.
The company’s management will webcast a corresponding conference call beginning at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Contacts
Investors:
InvestorRelations@nautilus.bio
Media:
Thermal for Nautilus Biotechnology
Kaustuva Das
Press@nautilus.bio